Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05612048 · ClinicalTrials.gov registry record · NA
A Study of Tooth Erosion in People With Esophagogastric Cancer
A NA study of Esophagogastric Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 174
- Enrollment target
- 1
- Study location
NCT05612048 is a NA study of Esophagogastric Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 174 participants, above the 48-participant average among 5 other Esophagogastric Cancer trials with a reported enrollment target (263% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05612048, a NA study of Esophagogastric Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 174 participants
- Enrollment target
- 1
- Study location
Study Summary
The researchers are doing this study to find out more about what may lead to the loss of tooth enamel (the thin outer covering of the tooth) and how often it happens in people with esophagogastric cancer, colorectal cancer, pancreatic cancer, breast cancer, head and neck cancer, or non-small cell lung cancer, or a healthy volunteer.
Conditions Studied
Interventions
- OTHER Survey
- OTHER Intra-oral camera
- OTHER Optional Salvia sample
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2022-11-03 |
| Est. Completion | 2027-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05612048
The ClinicalTrials.gov registry entry for NCT05612048 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 48-participant average among 5 other Esophagogastric Cancer trials with a reported enrollment target (263% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophagogastric Cancer appearing as the primary indexed condition, and to 3 interventions - of which Survey is the first listed.
NCT05612048 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05612048 about?
NCT05612048 is a clinical study titled "A Study of Tooth Erosion in People With Esophagogastric Cancer". The researchers are doing this study to find out more about what may lead to the loss of tooth enamel (the thin outer covering of the tooth) and how often it happens in people with esophagogastric cancer, colorectal cancer, pancreatic cancer, breast cancer, head and neck cancer, or non-small cell lu...
What is the current status of trial NCT05612048?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 174 participants. The study started on 2022-11-03. Estimated completion is 2027-11.
What conditions does trial NCT05612048 study?
This clinical trial studies the following conditions: Esophagogastric Cancer.
What interventions are being tested in trial NCT05612048?
The interventions under investigation include: Survey (OTHER), Intra-oral camera (OTHER), Optional Salvia sample (OTHER).
Who is sponsoring clinical trial NCT05612048?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05612048 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophagogastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Folfox+Irinotecan+Chemort In Esophageal Cancer
RECRUITING · Phase 2
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Amivantamab in People With Esophagogastric Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.